Long-term effects of cardiac stem cells transplantation to improve the electrophysiological stability and ventricular fibrillation threshold after myocardial infarction

doi:10.3969/j.issn.2095-4344.2015.10.008

Abstract

Abstract:

BACKGROUND: Our previous work has demonstrated that the electrophysiological stability and ventricular fibrillation threshold were distinctly improved in rats with myocardial infarction 6 weeks after cardiac stem cells transplantation (short- to mid-term).

OBJECTIVE: To observe the long-term effects of cardiac stem cells transplantation on the ventricular fibrillation threshold and electrophysiological stability in rats with heart failure post myocardial infarction.

METHODS: Twenty Sprague-Dawley rats with myocardial infarction were induced by the left anterior descending coronary artery ligation. Two weeks later, animals were randomized to receive the injection of cardiac stem cells labeled with PKH26 in PBS or PBS alone into the local infarct zone. Twelve weeks after the cardiac stem cells or PBS injection, the electrophysiological characteristics and ventricular fibrillation threshold were measured at the infarct zone, the infarct marginal zone and the non-infarct zone. Labeled cardiac stem cells were detected and the expression of connexin-43 and α-sarcomeric actin was examined in cryostat sections from each harvested heart.

RESULTS AND CONCLUSION: Compared with the PBS group, no significant differences were revealed in the unipolar electrogram activation recovery time and the correct activation recovery time in the infarct zone, the infarct marginal zone and the non-infarct zone in the cardiac stem cells group at 12 weeks post the cell transplantation (P > 0.05). There were no remarkable differences in the correct activation recovery time dispersion and induced malignant ventricular arrhythmias between the two groups (P > 0.05). No obvious differences were discovered in the ventricular fibrillation threshold in the infarct zone and infarct marginal zone in the cardiac stem cells group in contrast to the PBS group (P > 0.05), though a statistical significance could be found in the non-infarct zone between the two groups (P < 0.05). Labeled cardiac stem cells were identified in the infarct marginal zone and expressed connexin-43 and α-sarcomeric actin. It suggested that the beneficial effects of cardiac stem cells in modulating the electrophysiological stability and improving the ventricular fibrillation threshold faded away 12 weeks after cell transplantation. However, the mechanisms involved remained unclear.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: Myocytes, Cardiac, Heart Failure, Cardiac Electrophysiology, Ventricular Fibrillation

CLC Number:

R394.2

Chen Li-peng, Yan Ping, Guo Tian-zhu, Hou Jing-ying, Zheng Shao-xin, Zhou Chang-qing,Long Hui-bao, Zhong Ting-ting, Wang Tong. Long-term effects of cardiac stem cells transplantation to improve the electrophysiological stability and ventricular fibrillation threshold after myocardial infarction[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(10): 1516-1522.

Figures/Tables 6

References

[1]Labarthe DR, Dunbar SB. Global cardiovascular health promotion and disease prevention: 2011 and beyond. Circulation. 2012;125(21):2667-2676.
[2]Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378 (9806):1847-1857.
[3]Donndorf P, Strauer BE, Haverich A, et al. Stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart disease.Curr Pharm Biotechnol. 2013;14(1): 12-19.
[4]Pavo N, Charwat S, Nyolczas N, et al. Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. J Mol Cell Cardiol. 2014;75:12-24.
[5]Taylor J. Boosting acute myocardial infarction treatment with stem cells. Eur Heart J. 2014;35(16):1015-1016.
[6]Menasché P. Stem cell therapy for heart failure: are arrhythmias a real safety concern. Circulation. 2009;119(20): 2735-2740.
[7]Lalit PA, Hei DJ, Raval AN, et al. Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res. 2014;114(8):1328- 1345.
[8]Marbán E, Cho HC, Cingolani E. Taking the cells out of cell therapy. J Am Coll Cardiol. 2012;60(17):1707-1708.
[9]Narita T, Shintani Y, Ikebe C, et al. The use of cell-sheet technique eliminates arrhythmogenicity of skeletal myoblast-based therapy to the heart with enhanced therapeutic effects. Int J Cardiol. 2013;168(1):261-269.
[10]Li GR, Deng XL, Sun H, et al. Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006; 24(6): 1519-1528.
[11]Askar SF, Ramkisoensing AA, Atsma DE, et al. Engraftment patterns of human adult mesenchymal stem cells expose electrotonic and paracrine proarrhythmic mechanisms in myocardial cell cultures. Circ Arrhythm Electrophysiol. 2013; 6(2):380-391.
[12]Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369-2379.
[13]Liao SY, Liu Y, Siu CW, et al. Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm. 2010;7(12):1852-1859.
[14]Chong JJ, Yang X, Don CW, et al. Human embryonic-stem- cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273-277.
[15]van den Heuvel NH, van Veen TA, Lim B, et al. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes. J Mol Cell Cardiol. 2014;67:12-25.
[16]Keung W, Boheler KR, Li RA. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2014;5(1):17.
[17]Ye J, Yeghiazarians Y. Cardiac stem cell therapy: review of the native cardiac progenitor cells and future direction. J Cardiovasc Pharmacol. 2014;63(2):85-94.
[18]Hou J, Wang L, Jiang J, et al. Cardiac stem cells and their roles in myocardial infarction. Stem Cell Rev. 2013;9(3): 326-338.
[19]Wang T, Tang W, Sun S, et al. Improved outcomes of cardiopulmonary resuscitation in rats with myocardial infarction treated with allogenic bone marrow mesenchymal stem cells. Crit Care Med. 2009;37(3):833-839.
[20]Wang T, Sun S, Wan Z, et al. Effects of bone marrow mesenchymal stem cells in a rat model of myocardial infarction. Resuscitation. 2012;83(11):1391-1396.
[21]王彤,郑韶欣,周长青,等.心肌干细胞移植可改进心力衰竭大鼠室颤阈值和电生理的稳定性[J].中国组织工程研究和临床康复, 2011,15(36): 6753-6756.
[22]Zheng S, Zhou C, Weng Y, et al. Improvements of cardiac electrophysiologic stability and ventricular fibrillation threshold in rats with myocardial infarction treated with cardiac stem cells. Crit Care Med. 2011;39(5):1082-1088.
[23]Xia Y, Kongstad O, Hertervig E, et al. Activation recovery time measurements in evaluation of global sequence and dispersion of ventricular repolarization. J Electrocardiol. 2005; 38(1):28-35.
[24]Western D, Hanson B, Taggart P. Measurement bias in activation-recovery intervals from unipolar electrograms. Am J Physiol Heart Circ Physiol. 2015;308(4):H331-H338.
[25]Wang H, Tang W, Ristagno G, et al. The potential mechanisms of reduced incidence of ventricular fibrillation as the presenting rhythm in sudden cardiac arrest. Crit Care Med. 2009;37(1):26-31.
[26]Hsiao LC, Carr C, Chang KC, et al. Stem cell-based therapy for ischemic heart disease. Cell Transplant. 2013;22(4): 663-675.
[27]Poon E, Kong CW, Li RA. Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective. Mol Pharm. 2011;8(5): 1495-1504.
[28]Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell. 2013; 12(6):689-698.
[29]Simpson DL, Mishra R, Sharma S, et al. A strong regenerative ability of cardiac stem cells derived from neonatal hearts. Circulation. 2012;126(11 Suppl 1):S46-53.
[30]Ellison GM, Vicinanza C, Smith AJ, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell. 2013;154(4):827-842.
[31]El Haddad M, Houben R, Stroobandt R, et al. Novel algorithmic methods in mapping of atrial and ventricular tachycardia. Circ Arrhythm Electrophysiol. 2014;7(3):463-472.
[32]Trevisi N, Silberbauer J, Radinovic A, et al. New diagnostic criteria for identifying left-sided ventricular ectopy using non-contact mapping and virtual unipolar electrogram analysis. Europace. 2015;17(1):108-116.
[33]Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126(11 Suppl 1):S54-64.
[34]Fontes MS, van Veen TA, de Bakker JM, et al. Functional consequences of abnormal Cx43 expression in the heart. Biochim Biophys Acta. 2012;1818(8):2020-2029.
[35]Wu W, Li Y, Lu Z, et al. Increased susceptibility to ischemia-induced ventricular tachyarrhythmias in depressed rats: Involvement of reduction of connexin 43. Exp Ther Med. 2012;3(2):192-194.
[36]Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A. 2003;100(21): 12313-12318.
[37]Bolli R, Tang XL, Sanganalmath SK, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation. 2013;128(2):122-131.
[38]Amsalem Y, Mardor Y, Feinberg MS, et al. Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium. Circulation. 2007;116(11 Suppl): I38-45.
[39]Hong KU, Guo Y, Li QH, et al. c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One. 2014;9(5):e96725.
[40]Gullo C, de Almeida Zia VA, Vilela-Martin JF. Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy. Recent Pat Cardiovasc Drug Discov. 2014;9(1):28-37.
[41]von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8(1):71-78.